奥美沙坦 | 144689-78-1

• 物质功能分类: 原料药 - 循环系统用药 - 抗高血压病药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 奥美沙坦
• 中文别名: 4-(1-羟基-1-甲基乙基)-2-丙基-1-[2'-(四唑-5-基)苯基]苯基]甲基咪唑-5-羧酸；2,3-二羟基-2-丁烯基-4-(1-羟基-1-甲基乙基)-2-丁基-1-[4-(2-1H-四唑-5-苯基)苄基]咪唑-5-羧酸酯环-2,3-碳酸酯；奥美沙坦酯
• 英文名称: (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
• 英文别名: N-Butyl Olmesartan Medoxomil；(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-butyl-5-(2-hydroxypropan-2-yl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
• CAS: 144689-78-1
• 化学式: C₃₀H₃₂N₆O₆
• 分子量: 572.621
• InChiKey: UREFBEDUPPNTPO-UHFFFAOYSA-N

物化性质

• 沸点：
  808.7±75.0 °C(Predicted)
• 密度：
  1.36

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  42
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  154
• 氢给体数：
  2
• 氢受体数：
  10

安全信息

• 海关编码：
  2934999090

制备方法与用途

沙坦类抗高血压药

奥美沙坦酯是一种沙坦类抗高血压药，1991年由日本三共株式会社研制成功，在众多国家获得专利保护，专利号为：EP0503785，专利优先国为日本；该产品合成工艺在中国申请了相关专利，CN1045770及CN1381453。它克服了血管紧张素转换酶抑制剂(ACEI)的缺点并保存其优点，其作用类似但不引起ACEI类药物导致的干咳、皮疹和血管神经性水肿等作用，不良反应较小，病人耐受性好，在轻中度高血压治疗中疗效良好，在临床上比较受欢迎。
奥美沙坦酯具有强效的降压作用，口服后在小肠壁完全去酯转化成活性代谢产物奥美沙坦（Olmesartan），奥美沙坦是一种选择性非肽类血管紧张素II受体拮抗剂，通过选择性阻断血管紧张素Ⅱ与血管平滑肌AT1受体的结合而阻断血管紧张素Ⅱ的收缩血管作用，每天5mg、20mg和40mg的用药剂量，可分别降低坐位收缩压12.4mmHg、15.1mmHg和17.6mmHg；降低坐位舒张压9.8mmHg、12.2mmHg和13.1mmHg。在小鼠和大鼠急性毒性实验中，单次口服给药最大剂量达2000mg/kg时，仍没有致死结果出现。狗的最小致死量大于1500mg/kg。未见致癌性、致畸性、致突变性、生殖毒性和遗传毒性。
常见的沙坦类抗高血压药物：缬沙坦、厄贝沙坦、替米沙坦，坎地沙坦酯、依普沙坦、他索沙坦、奥美沙坦酯。

用途 

抗高血压药

文献信息

• 1-Biphenylimidazole derivatives, their preparation and their therapeutic use
  申请人：Sankyo Company Limited

  公开号：EP0503785A1

  公开（公告）日：1992-09-16

  Compounds of formula (I): in which: R¹ is alkyl or alkenyl; R² and R³ are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R⁴ is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula -SiRaRbRc, in which Ra, Rb and Rc are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R⁵ is carboxy or a group of formula -CONR⁸R⁹, in which R⁸ and R⁹ are hydrogen atoms or alkyl, or R⁸ and R⁹ together form alkylene; R⁶ is hydrogen, alkyl, alkoxy or halogen; R⁷ is carboxy or tetrazol-5-yl; and pharmaceutically acceptable salts and esters thereof have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. They may be prepared, inter alia, by reacting a biphenylmethyl compound with an imidazole compound.

  式(I)的化合物中：其中，R¹是烷基或烯基；R²和R³是氢、烷基、烯基、环烷基、芳基烷基、芳基或与环烷基融合的芳基；R⁴是氢、烷基、酰基烷基、烯酰基烷基、芳基羰基、烷氧羰基、四氢吡喃基、四氢硫吡喃基、四氢噻吩基、四氢呋喃基、式为-SiRaRbRc的基团，其中Ra、Rb和Rc是烷基或芳基、烷氧甲基、（烷氧基）甲基、卤代烷氧甲基、芳基烷基、芳基或酰氧甲氧羰基；R⁵是羧基或式为-CONR⁸R⁹的基团，其中R⁸和R⁹是氢原子或烷基，或R⁸和R⁹一起形成亚烷基；R⁶是氢、烷基、烷氧基或卤素；R⁷是羧基或四唑-5-基；其药学上可接受的盐和酯具有降压活性，可用于治疗和预防高血压。它们可以通过将联苯甲基化合物与咪唑化合物反应制备而成。
• MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2174666A1

  公开（公告）日：2010-04-14

  The present invention provides a medicament for preventing or treating Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimer's disease, comprising an angiotensin II receptor blocker as an active ingredient. A prophylactic or therapeutic agent for Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimer's disease, comprising an angiotensin II receptor blocker as an active ingredient.

  本发明提供了一种预防或治疗阿尔茨海默病或轻度认知障碍（包括阿尔茨海默病在内的认知障碍的早期状态）的药物，其活性成分包括血管紧张素II受体阻滞剂。 一种阿尔茨海默病或轻度认知障碍（包括阿尔茨海默病在内的认知障碍的早期状态）的预防或治疗药物，包含一种血管紧张素 II 受体阻滞剂作为活性成分。
• PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1884240B1

  公开（公告）日：2009-11-11
• Pharmaceutical for prevention or treatment of bone metabolic disease
  申请人：Morishita Ryuuichi

  公开号：US20090082411A1

  公开（公告）日：2009-03-26

  A method for treating a bone metabolic disease by administering to a human a pharmacologically effective amount of an angiotensin II receptor antagonist which is a compound of the following formula (I), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof: wherein R 1 represents a C 1 -C 4 alkyl; R 2 and R 3 are the same or different and each represent hydrogen or a C 1 -C 4 alkyl; R 4 represents hydrogen or a C 1 -C 4 alkyl; R 5 represents hydrogen, a C 1 -C 4 alkyl, a C 2 -C 5 alkanoyloxymethyl, 1 -(C 2 -C 5 alkanoyloxy)ethyl, a C 1 -C 4 alkoxycarbonyloxymethyl, 1 -(C 1 -C 4 alkoxycarbonyloxy)ethyl, a ( 5 -methyl- 2 -oxo- 1,3 -dioxolen- 4 -yl)methyl, a ( 5 -phenyl- 2 -oxo- 1,3 -dioxolen- 4 -yl)methyl or a phthalidyl; and R 6 represents a carboxy or a tetrazole- 5 -yl.
• MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE
  申请人：Morishita Ryuichi

  公开号：US20100130567A1

  公开（公告）日：2010-05-27

  A method of treating or preventing Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimers' disease by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of improving cerebral circulation or cerebral blood flow disorder by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of treating or preventing amyloid β-induced brain disfunction by administering a pharmacologically effective amount of an angiotensin II receptor blocker.